Detalhe da pesquisa
1.
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Breast Cancer Res
; 26(1): 69, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38650031
2.
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.
J Surg Oncol
; 126(8): 1494-1503, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111443
3.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 22(1): 9, 2020 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969184
4.
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 21(1): 133, 2019 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31796073
5.
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
J Clin Oncol
; 42(13): 1520-1530, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315963
6.
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
Front Oncol
; 13: 1139347, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37305569
7.
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Clin Cancer Res
; 27(6): 1612-1622, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33203645
8.
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
JAMA Oncol
; 3(3): 335-341, 2017 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27812689
9.
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
JAMA Oncol
; 2(9): 1162-9, 2016 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27270348
10.
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
J Natl Cancer Inst
; 105(13): 989-92, 2013 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23821759
11.
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
Clin Cancer Res
; 18(23): 6531-41, 2012 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23045248